Option chain shows key data for Zenas BioPharma's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Zenas BioPharma.

Zenas BioPharma (NASDAQ:ZBIO) Stock, Option Chain

ZENAS BIOPHARMA INC

ProShares UltraPro Short NASDAQ Biotechnology

Zenas BioPharma

Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.

ZBIO

Analyst Color

Biotech

News

Health Care

Initiation

Analyst Ratings

Movers

Trading Ideas

General

AMGN

Wedbush initiates coverage on Zenas BioPharma, citing strong potential for obexelimab in autoimmune diseases, with key clinical data expected in 2025 and 2026.

Zenas BioPharma Gains Outperform Rating From Analyst As Key Autoimmune Trials Progress

Recent Gains

Pre-Market Outlook

Markets

ANAB

DOGZ

GHRS

IRON

PRGS

SEPN

Progress Software, Disc Medicine And Other Big Stocks Moving Lower In Wednesday&#39;s Pre-Market Session

Wall Street

ADUS

ANRO

GRND

USPH

This Addus HomeCare Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Zenas BioPharma Inc

Press Releases

Zenas BioPharma to Participate in Upcoming Healthcare Investor Conferences

Zenas BioPharma Completes Targeted Enrollment of the Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD)

Earnings

Zenas BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

Zenas BioPharma to Present at the Guggenheim SMID Cap Biotech Conference

Zenas BioPharma Announces Key 2024 Accomplishments and 2025 Business Objectives to Support the Global Development and Commercialization of Therapies for Autoimmune Diseases

Management

Zenas BioPharma Appoints Lisa von Moltke, M.D., as Head of Research and Development and Chief Medical Officer

Rosen Law Firm Encourages Zenas BioPharma, Inc. Investors to Inquire About Securities Class Action Investigation – ZBIO

ZBIO Investor News: Rosen Law Firm Encourages Zenas BioPharma, Inc. Investors to Inquire About Securities Class Action Investigation - ZBIO

Legal

Zenas BioPharma, Inc. Announcement: If You Have Suffered Losses in Zenas BioPharma, Inc. (NASDAQ: ZBIO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

Comments

Zenas BioPharma

Zenas BioPharma (ZBIO) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga